Literature DB >> 2073794

The human CBL oncogene.

W Y Langdon1, T J Blake.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2073794     DOI: 10.1007/978-3-642-75889-8_20

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


× No keyword cloud information.
  6 in total

1.  The N terminus of Cbl-c regulates ubiquitin ligase activity by modulating affinity for the ubiquitin-conjugating enzyme.

Authors:  Philip E Ryan; Nina Sivadasan-Nair; Marion M Nau; Sarah Nicholas; Stanley Lipkowitz
Journal:  J Biol Chem       Date:  2010-06-04       Impact factor: 5.157

2.  The Casitas B lineage lymphoma (Cbl) mutant G306E enhances osteogenic differentiation in human mesenchymal stromal cells in part by decreased Cbl-mediated platelet-derived growth factor receptor alpha and fibroblast growth factor receptor 2 ubiquitination.

Authors:  Nicolas Sévère; Hichem Miraoui; Pierre J Marie
Journal:  J Biol Chem       Date:  2011-05-19       Impact factor: 5.157

3.  Cbl-c ubiquitin ligase activity is increased via the interaction of its RING finger domain with a LIM domain of the paxillin homolog, Hic 5.

Authors:  Philip E Ryan; Stephen C Kales; Rajgopal Yadavalli; Marion M Nau; Han Zhang; Stanley Lipkowitz
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

4.  Loss of function Cbl-c mutations in solid tumors.

Authors:  Silvano Rakeem Daniels; Mariya Liyasova; Stephen C Kales; Marion M Nau; Philip E Ryan; Jeffrey E Green; Stanley Lipkowitz
Journal:  PLoS One       Date:  2019-07-01       Impact factor: 3.240

Review 5.  All Good Things Must End: Termination of Receptor Tyrosine Kinase Signal.

Authors:  Azzurra Margiotta
Journal:  Int J Mol Sci       Date:  2021-06-14       Impact factor: 5.923

6.  Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A.

Authors:  Stephen C Kales; Marion M Nau; Anand S Merchant; Stanley Lipkowitz
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.